248 related articles for article (PubMed ID: 18237248)
1. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
3. Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer.
Papadopoulou E; Simopoulos K; Tripsianis G; Tentes I; Anagnostopoulos K; Sivridis E; Galazios G; Kortsaris A
Neoplasma; 2007; 54(5):365-73. PubMed ID: 17918664
[TBL] [Abstract][Full Text] [Related]
4. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
5. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
Souder C; Leitzel K; Ali SM; Demers L; Evans DB; Chaudri-Ross HA; Hackl W; Hamer P; Carney W; Lipton A
Cancer; 2006 Nov; 107(10):2337-45. PubMed ID: 17048231
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu Ile655Val polymorphism and the risk of breast cancer.
Siddig A; Mohamed AO; Kamal H; Awad S; Hassan AH; Zilahi E; Al-Haj M; Bernsen R; Adem A
Ann N Y Acad Sci; 2008 Sep; 1138():84-94. PubMed ID: 18837888
[TBL] [Abstract][Full Text] [Related]
7. Human epithelial growth factor receptor 2[Ile655Val] polymorphism and risk of breast fibroadenoma.
Zubor P; Kajo K; Stanclova A; Szunyogh N; Galo S; Dussan CA; Minarik G; Visnovsky J; Danko J
Eur J Cancer Prev; 2008 Feb; 17(1):33-8. PubMed ID: 18090908
[TBL] [Abstract][Full Text] [Related]
8. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia.
Zúbor P; Vojvodová A; Danko J; Kajo K; Szunyogh N; Lasabová Z; Biringer K; Visnovský J; Dókus K; Galajda P; Plank L
Neoplasma; 2006; 53(1):49-55. PubMed ID: 16416013
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
10. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
12. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
Naidu R; Yip CH; Taib NA
Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
[TBL] [Abstract][Full Text] [Related]
14. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
[TBL] [Abstract][Full Text] [Related]
15. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
[TBL] [Abstract][Full Text] [Related]
16. Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women.
Kamali-Sarvestani E; Talei AR; Merat A
Cancer Lett; 2004 Nov; 215(1):83-7. PubMed ID: 15374636
[TBL] [Abstract][Full Text] [Related]
17. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis.
Ishitobi M; Miyoshi Y; Ando A; Hasegawa S; Egawa C; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2003 Apr; 9(4):1376-80. PubMed ID: 12684407
[TBL] [Abstract][Full Text] [Related]
18. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
19. HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.
Bewick M; Conlon M; Gerard S; Lee H; Parissenti AM; Zhang L; Glück S; Lafrenie RM
Bone Marrow Transplant; 2001 Apr; 27(8):847-53. PubMed ID: 11477443
[TBL] [Abstract][Full Text] [Related]
20. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]